Publications

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
EBioMedicine 2018 Feb 5. Epub 2018 Feb 5.
Pangaea Oncology, Laboratory of Molecular Biology, Coyote Reserach Group, Quirón-Dexeus University Institute, Barcelona, Spain; Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain; Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain; Institut Català d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain. Electronic address:



IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
J Neurooncol 2017 Nov 7;135(2):273-284. Epub 2017 Sep 7.
Medical Oncology Service, Catalan Institute of Oncology (ICO), Hospital Germans Trias i Pujol, Ctra Canyet s/n, 08916, Badalona, Barcelona, Spain.




Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.
Cancer Cell 2017 Aug;32(2):238-252.e9
Department of Neurosurgery, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Brain Tumor Center Amsterdam, VU University Medical Center, Cancer Center Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands; Department of Neurology, Massachusetts General Hospital and Neuroscience Program, Harvard Medical School, 149 13(th) Street, Charlestown, MA 02129, USA. Electronic address:

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Lung Cancer 2017 Jun 22;108:154-160. Epub 2017 Mar 22.
Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain; Dr. Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain; Molecular Oncology Research Foundation (MORe), Barcelona, Spain; Universitat Autònoma de Barcelona (UAB) Campus Can Ruti, Carretera de Canyet s/n, 08916 Badalona, Barcelona, Spain. Electronic address:


Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
J Clin Oncol 2017 May 13;35(13):1403-1410. Epub 2017 Mar 13.
Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain.

Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
Int J Biol Markers 2017 Mar 2;32(1):e90-e95. Epub 2017 Mar 2.
 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona - Spain.

Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery.
Clin Lung Cancer 2017 Mar 9;18(2):178-188.e4. Epub 2016 Nov 9.
Cancer Biology and Precision Medicine Program, Hospital Germans Trias i Pujol, Catalan Institute of Oncology, Badalona, Spain; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain; Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Spain.



High BIM mRNA levels are associated with longer survival in advanced gastric cancer.
Oncol Lett 2017 Mar 1;13(3):1826-1834. Epub 2017 Feb 1.
The Comprehensive Cancer Centre of Drum Tower Hospital, Department of Oncology, The Affiliated Drum Tower Hospital of Nanjing University, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu 210008, P.R. China.




Human endogenous retroviruses and cancer.
Cancer Biol Med 2016 Dec;13(4):483-488
Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona 08028, Spain; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias I Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, 08916, Spain; Fundación Molecular Oncology Research, Barcelona 08028, Spain.






mutations in the circulating free DNA (cfDNA) of non-small cell lung cancer (NSCLC) patients.
Transl Lung Cancer Res 2016 Oct;5(5):511-516
Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 08028 Barcelona, Spain;; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Crta de Canyet s/n, 08016 Badalona, Spain;; Autonomous University of Barcelona (UAB), Campus Can Ruti, Crta de Canyet s/n, 08016 Badalona, Spain;; Molecular Oncology Research (MORe) Foundation, 08028 Barcelona, Spain.

Fusion gene and splice variant analyses in liquid biopsies of lung cancer patients.
Transl Lung Cancer Res 2016 Oct;5(5):525-531
Pangaea Biotech, Laboratory of Oncology, Quirón Dexeus University Hospital, Barcelona, Spain;; Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain;; Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain;; Autonomous University of Barcelona (UAB), Campus Can Ruti, Badalona, Spain;; Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

Usefulness of circulating free DNA for monitoring epidermal growth factor receptor mutations in advanced non-small cell lung cancer patients: a case report.
Transl Lung Cancer Res 2016 Oct;5(5):532-537
Pangaea Biotech, Medical Oncology Laboratory, Dexeus University Hospital, Quirónsalud Group, Barcelona, Spain;; Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Dexeus University Hospital-Quirónsalud Group, Barcelona, Spain;; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Triasi Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.


MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
Gastric Cancer 2016 Jul 24;19(3):778-88. Epub 2015 Sep 24.
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, 321 Zhongshan Road, Nanjing, 210008, China.


Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
J Clin Oncol 2016 Apr 1;34(11):1223-30. Epub 2016 Feb 1.
Elisabeth Brambilla and Sylvie Lantuejoul, Institut Albert Bonniot-Institut National de la Santé et de la Recherche Médicale U823; and Centre Hospitalier Universitaire Albert Michallon, Grenoble; Gwénaël Le Teuff, Sophie Marguet, Ariane Dunant, Thierry Le Chevalier, and Jean-Charles Soria, Institut Gustave Roussy, Villejuif; Gwénaël Le Teuff, Sophie Marguet, Ariane Dunant, Thierry Le Chevalier, and Jean-Charles Soria, Université Paris-Sud, Orsay; Gwénaël Le Teuff, Université Paris-Saclay, Saint-Aubin; Jean-Yves Douillard, Centre René Gauducheau Institut de Cancerologie de l'Ouest, Saint-Herblain, France; Stephen Graziano, State University of New York Upstate Medical University, Syracuse, NY; Robert Pirker and Martin Filipits, Medical University of Vienna, Vienna; Helmut Popper, Medical University of Graz, Graz, Austria; Rafael Rosell, Catalan Institute of Oncology, Barcelona, Spain; Robert Kratzke, University of Minnesota, Minneapolis, MN; Frances A. Shepherd and Ming Sound Tsao, Princess Margaret Cancer Centre; Frances A. Shepherd and Ming Sound Tsao, University of Toronto, Toronto; and Lesley Seymour, Queen's University, Kingston, Ontario, Canada.



Cellular and molecular biology of small cell lung cancer: an overview.
Transl Lung Cancer Res 2016 Feb;5(1):2-15
1 Instituto Oncolόgico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Division of Thoracic Oncology, European Institute of Oncology (IEO), Milan, Italy ; 4 Pangaea Biotech, Barcelona, Spain ; 5 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 7 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain.

Cancer stem cells in small cell lung cancer.
Transl Lung Cancer Res 2016 Feb;5(1):16-25
1 Pangaea Biotech S.L, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Santa Maria delle Croci City Hospital, Ravenna, Italy ; 3 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 4 Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 5 Fundación Molecular Oncology Research, Barcelona, Spain.

Targeted drugs in small-cell lung cancer.
Transl Lung Cancer Res 2016 Feb;5(1):51-70
1 Medical Oncology Unit, Department of Human Pathology "G. Barresi", University of Messina, Messina, Italy ; 2 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy ; 4 Pangaea Biotech, Barcelona, Spain ; 5 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.


BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors.
Melanoma Res 2015 Dec;25(6):486-95
aTranslational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital bPangaea Biotech S.L cHospital Vall d'Hebron dCatalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona eMORe Foundation, Barcelona fHospital Central Asturias, Oviedo gPivotal SL, Madrid hCUN, Pamplona, Spain.


Cancer stem cells and immunoresistance: clinical implications and solutions.
Transl Lung Cancer Res 2015 Dec;4(6):689-703
1 Pangaea Biotech S.L., Quirón-Dexeus University Hospital, Barcelona, Spain ; 2 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 3 Instituto Oncológico Dr Rosell, Quirón-Dexeus University Hospital, Barcelona, Spain ; 4 Fundación Molecular Oncology Research, Barcelona, Spain.

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer.
Transl Lung Cancer Res 2015 Dec;4(6):704-12
1 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 2 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 3 Istituto Nazionale Tumori, Milano, Italy ; 4 Italian Medicines Agency, Roma, Italy ; 5 Pangaea Biotech, Barcelona, Spain ; 6 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 8 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain.

Platelets and their role in cancer evolution and immune system.
Transl Lung Cancer Res 2015 Dec;4(6):713-20
1 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Pangaea Biotech, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Spain.

Integrating the molecular background of targeted therapy and immunotherapy in lung cancer: a way to explore the impact of mutational landscape on tumor immunogenicity.
Transl Lung Cancer Res 2015 Dec;4(6):721-7
1 Medical Oncology, Department of Medicine, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 2 Pangaea Biotech, Barcelona, Spain ; 3 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 6 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Spain.

Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role.
Transl Lung Cancer Res 2015 Dec;4(6):728-42
1 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 2 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Pangaea Biotech, Barcelona, Spain ; 4 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain ; 5 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 6 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain.

cfDNA analysis from blood in melanoma.
Ann Transl Med 2015 Nov;3(20):309
1 Laboratory of Oncology/Pangaea Biotech S.L, Hospital Quiron Dexeus, Barcelona, Spain ; 2 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 3 Catalan Institute of Oncology, Hospital Germans Trias i Pujol Badalona, Barcelona, Spain.

Melanoma: oncogenic drivers and the immune system.
Ann Transl Med 2015 Oct;3(18):265
1 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Pangaea Biotech, Quirón Dexeus University Institute, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy ; 6 Instituto Oncológico de Córdoba, Córdoba, Argentina ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 8 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain.

Other targeted drugs in melanoma.
Ann Transl Med 2015 Oct;3(18):266
1 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain ; 2 Vall D'Hebron Institute of Oncology and Universitat Autonoma de Barcelona, Barcelona, Spain ; 3 Immunology Department, CNICV, Madrid, Spain ; 4 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina, Italy ; 5 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 6 Pangaea Biotech S.L, Barcelona, Spain ; 7 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain ; 8 Fundación Molecular Oncology Research, Barcelona, Spain.

Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression.
Anticancer Res 2015 Sep;35(9):4871-5
Cancer Biology and Precision Medicine Program, Germans Trias i Pujol University Hospital, Badalona, Spain Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona, Spain Molecular Oncology Research Foundation (MORe), Barcelona, Spain


Advances in immunotherapy for treatment of lung cancer.
Cancer Biol Med 2015 Sep;12(3):209-22
1 Albert Einstein Medical Center, Philadelphia 19141, USA ; 2 Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona 08028, Spain ; 3 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98100, Italy ; 4 Pangaea Biotech S.L, Barcelona 08028, Spain ; 5 Cancer Biology & Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona 08916, Spain ; 6 Fundación Molecular Oncology Research, Barcelona 08028, Spain.

Erratum to Assays for predicting and monitoring responses to lung cancer immunotherapy.
Cancer Biol Med 2015 Sep;12(3):259
1 Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona 08028, Spain ; 2 Dr. Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona 08028, Spain ; 3 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona 08916, Spain.

Predictive factors for immunotherapy in melanoma.
Ann Transl Med 2015 Sep;3(15):208
1 Pangaea Biotech, 2 Dr Rosell Oncology Institute, Quirón Dexeus University Hospital, 08028 Barcelona, Spain ; 3 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, 08916 Badalona, Spain ; 4 Molecular Oncology Research Foundation (MORe), Barcelona, Spain.

Assays for predicting and monitoring responses to lung cancer immunotherapy.
Cancer Biol Med 2015 Jun;12(2):87-95
1 Pangaea Biotech, Quirón Dexeus University Hospital, Barcelona 08028, Spain ; 2 Dr. Rosell Oncology Institute, Quirón Dexeus University Hospital, Barcelona 08028, Spain ; 3 Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona 08916, Spain.


Targeting PD-1/PD-L1 in lung cancer: current perspectives.
Lung Cancer (Auckl) 2015 31;6:55-70. Epub 2015 Jul 31.
Translational Cancer Research Unit, Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; Pangaea Biotech SL, Barcelona, Spain; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Badalona, Barcelona, Spain; Fundación Molecular Oncology Research, Barcelona, Spain.



Liquid Biopsy in Non-Small Cell Lung Cancer.
Front Med (Lausanne) 2016 23;3:69. Epub 2016 Dec 23.
Instituto Oncológico Dr Rosell, Quirón Dexeus University Hospital, Barcelona, Spain; Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Badalona, Spain.



Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
N Engl J Med 2017 08 6;377(9):829-838. Epub 2017 Jun 6.
From Lausanne University Hospital, Lausanne (S.P.), and F. Hoffmann-La Roche, Basel (A.Z., E.M., S. Golding, B.B., J.N.) - both in Switzerland; University of Colorado, Denver (D.R.C.); Massachusetts General Hospital, Boston (A.T.S.); University of Michigan, Ann Arbor (S. Gadgeel); Samsung Medical Center, Sungkyunkwan University School of Medicine (J.S.A.), and Seoul National University Hospital (D.-W.K.) - both in Seoul, South Korea; Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.); Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France (M.P.); Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland (R.D.); Catalan Institute of Oncology, Barcelona (R.R.); Roche Innovation Center, New York (P.N.M.); and State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong (T.M.).




Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Ther Adv Med Oncol 2018 18;10:1758834017749748. Epub 2018 Jan 18.
Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain Institut d'Investigació en Ciències Germans Trias i Pujol, Badalona, Spain Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona, Spain.

OF